The study comprises 2 parts: Phase 1/2 and Phase 2 Northern Hemisphere (NH). The primary objective of Phase 1/2 is to evaluate the safety and reactogenicity of 3 dose levels of mRNA-1010 vaccine administered as a single dose. The primary objective of Phase 2 NH is to evaluate the humoral immunogenicity of mRNA-1010 vaccine relative to that of an active comparator against vaccine-matched influenza A and B strains.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, learn about Clinical
|Ages Eligible for Study
|Min Age: 18 years - Max Age: N/A
|Sexes Eligible for Study
|Accepts Healthy Volunteers